PL1653943T3 - Pochodne katecholu do leczenia raka - Google Patents

Pochodne katecholu do leczenia raka

Info

Publication number: PL1653943T3
Authority: PL; Poland
Prior art keywords: alkyl; medicament; cancer; treatment; aryl
Prior art date: 2003-06-25

Application number

PL04777151T

Other languages

English (en)

Other versions

PL1653943T6 (pl

Inventor

John C Reed

Maurizio Pellecchia

Original Assignee

The Burnham Inst La Jolla

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-25

Filing date

2004-06-25

Publication date

2008-09-30

2004-06-25 Application filed by The Burnham Inst La Jolla filed Critical The Burnham Inst La Jolla

2008-09-30 Publication of PL1653943T3 publication Critical patent/PL1653943T3/pl

2009-02-27 Publication of PL1653943T6 publication Critical patent/PL1653943T6/pl

Links

206010028980 Neoplasm Diseases 0.000 title abstract 3
201000011510 cancer Diseases 0.000 title abstract 3
150000005206 1,2-dihydroxybenzenes Chemical class 0.000 title 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 3
239000003814 drug Substances 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000003034 chemosensitisation Effects 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PL04777151T 2003-06-25 2004-06-25 Pochodne katecholu do leczenia raka PL1653943T6 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US48288603P	2003-06-25	2003-06-25
EP04777151A EP1653943B3 (en)	2003-06-25	2004-06-25	Catechol derivatives for the treatment of cancer
PCT/US2004/020569 WO2005009434A2 (en)	2003-06-25	2004-06-25	Compounds and methods for inducing apoptosis in cancer cells

Publications (2)

Publication Number	Publication Date
PL1653943T3 true PL1653943T3 (pl)	2008-09-30
PL1653943T6 PL1653943T6 (pl)	2009-02-27

Family

ID=34102647

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04777151T PL1653943T6 (pl)	2003-06-25	2004-06-25	Pochodne katecholu do leczenia raka

Country Status (13)

Country	Link
US (3)	US7812058B2 (pl)
EP (2)	EP1653943B3 (pl)
JP (2)	JP2007524633A (pl)
AT (2)	ATE387911T1 (pl)
AU (1)	AU2004258867B2 (pl)
CA (1)	CA2529507C (pl)
DE (2)	DE602004028880D1 (pl)
DK (1)	DK1653943T4 (pl)
ES (2)	ES2351581T3 (pl)
PL (1)	PL1653943T6 (pl)
PT (1)	PT1653943E (pl)
SI (1)	SI1653943T1 (pl)
WO (1)	WO2005009434A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7432304B2 (en) *	2001-05-30	2008-10-07	The Regents Of The University Of Michigan	Small molecule antagonists of Bcl-2 family proteins
AU2002360335A1 (en) *	2001-11-01	2003-05-12	The Regents Of The University Of Michigan	Small molecule inhibitors targeted at bcl-2
ATE387911T1 (de)	2003-06-25	2008-03-15	Burnham Inst	Katecholderivate zur behandlung von krebs
SG151299A1 (en)	2004-03-25	2009-04-30	Univ Michigan	Gossypol co-crystals and the use thereof
US20060144723A1 (en) *	2004-11-02	2006-07-06	Mary Fuller	Device for securing valuables
CN101883486B (zh) *	2007-10-01	2014-09-17	阿森达治疗学股份有限公司	制备r-棉酚l-苯丙氨醇二烯胺的方法
WO2009052443A1 (en)	2007-10-19	2009-04-23	Burnham Institute For Medical Research	Naphthalene-based inhibitors of anti-apoptotic proteins
FR2924712B1 (fr)	2007-12-06	2012-12-21	Univ Maine	Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications
GB0725077D0 (en) *	2007-12-21	2008-01-30	Univ Murcia	Antifolate com[ounds for the treatment of melanoma
WO2009126172A1 (en) *	2008-04-11	2009-10-15	The Trustees Of Columbia University In The City Of New York	Resistance to polyphenon e due to increased bcl-2 expression
WO2010019914A2 (en) *	2008-08-14	2010-02-18	The Uab Research Foundation	Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
US8487131B2 (en)	2009-04-15	2013-07-16	Sanford-Burnham Medical Research Institute	Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
CA2758491A1 (en)	2009-04-15	2010-10-21	Sanford-Burnham Medical Research Institute	Naphthalene-based inhibitors of anti-apoptotic proteins
US8772264B2 (en)	2009-08-04	2014-07-08	Mayo Foundation For Medical Education And Research	Methods of treating hematologic cancers
EA201270347A1 (ru)	2009-10-08	2012-11-30	Санфорд-Бернхам Медикал Ресерч Инститъют	Производные апогоссиполона в качестве противоопухолевых агентов
EP2956470A4 (en) *	2013-02-15	2016-12-07	Univ Michigan Regents	COMPOSITIONS AND METHODS PREVENTING THE RECRUITMENT OF DOT1L BY MLL HYBRID PROTEINS
US9655998B2 (en)	2014-08-07	2017-05-23	Cook Medical Technologies Llc	Encapsulated drug compositions and methods of use thereof
US9180226B1 (en)	2014-08-07	2015-11-10	Cook Medical Technologies Llc	Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US11241520B2 (en)	2014-08-07	2022-02-08	Cook Medical Technologies Llc	Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US10195213B2 (en)	2015-03-13	2019-02-05	Unity Biotechnology, Inc.	Chemical entities that kill senescent cells for use in treating age-related disease
RU2654711C1 (ru) *	2017-07-10	2018-05-22	Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ)	Средство, обладающее апоптоз-индуцирующей активностью
CN115281419A (zh) *	2018-04-20	2022-11-04	耐克创新有限合伙公司	带有板和中间流体填充囊的鞋底结构及其制造方法
CN110128290B (zh) *	2019-05-10	2022-04-29	江苏耐雀生物工程技术有限公司	红倍酚苯甲酰肼衍生物、中间体、制备方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4559157A (en)	1983-04-21	1985-12-17	Creative Products Resource Associates, Ltd.	Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr)	1983-08-30	1985-04-24	Oreal	Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en)	1987-06-23	1989-04-11	Neutrogena Corporation	Skin protective composition
US4992478A (en)	1988-04-04	1991-02-12	Warner-Lambert Company	Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
US5385936A (en) *	1990-07-12	1995-01-31	The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services	Gossypol acetic acid for the treatment of cancer
US5804567A (en) *	1996-07-18	1998-09-08	Cancer Institute (Hospital), Chinese Academy Of Medical Sciences	Method of increasing the effectiveness of anti-metabolites
JPH1036260A (ja) *	1996-07-18	1998-02-10	Mitsui Norin Kk	抗ガン剤の効力増強方法
US6428818B1 (en) *	1999-03-30	2002-08-06	Purdue Research Foundation	Tea catechin formulations and processes for making same
CN100490791C (zh) *	2000-12-15	2009-05-27	维克沃姆有限公司	治疗与新血管生成相关疾病的组合物及方法
JP2005515158A (ja) *	2001-05-30	2005-05-26	ザリージェンツオブザユニバーシティオブミシガン	Ｂｌｃ−２ファミリータンパク質の小分子アンタゴニスト
US7432304B2 (en) *	2001-05-30	2008-10-07	The Regents Of The University Of Michigan	Small molecule antagonists of Bcl-2 family proteins
ATE387911T1 (de) *	2003-06-25	2008-03-15	Burnham Inst	Katecholderivate zur behandlung von krebs

2004
- 2004-06-25 AT AT04777151T patent/ATE387911T1/de not_active IP Right Cessation
- 2004-06-25 DE DE602004028880T patent/DE602004028880D1/de active Active
- 2004-06-25 EP EP04777151A patent/EP1653943B3/en not_active Not-in-force
- 2004-06-25 AT AT08003839T patent/ATE478663T1/de not_active IP Right Cessation
- 2004-06-25 US US10/877,781 patent/US7812058B2/en not_active Expired - Fee Related
- 2004-06-25 PL PL04777151T patent/PL1653943T6/pl unknown
- 2004-06-25 EP EP08003839A patent/EP1938816B1/en not_active Not-in-force
- 2004-06-25 PT PT04777151T patent/PT1653943E/pt unknown
- 2004-06-25 DE DE602004012279T patent/DE602004012279T3/de active Active
- 2004-06-25 DK DK04777151T patent/DK1653943T4/da active
- 2004-06-25 SI SI200430628T patent/SI1653943T1/sl unknown
- 2004-06-25 WO PCT/US2004/020569 patent/WO2005009434A2/en active Application Filing
- 2004-06-25 JP JP2006517702A patent/JP2007524633A/ja active Pending
- 2004-06-25 CA CA2529507A patent/CA2529507C/en not_active Expired - Fee Related
- 2004-06-25 AU AU2004258867A patent/AU2004258867B2/en not_active Ceased
- 2004-06-25 ES ES08003839T patent/ES2351581T3/es active Active
- 2004-06-25 ES ES04777151T patent/ES2303096T7/es active Active
2010
- 2010-10-07 US US12/900,319 patent/US8367644B2/en not_active Expired - Fee Related
2011
- 2011-09-29 JP JP2011215077A patent/JP2012025767A/ja active Pending
- 2011-12-19 US US13/329,611 patent/US20120269901A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20120269901A1 (en)	2012-10-25
EP1938816A3 (en)	2008-08-06
US20050027000A1 (en)	2005-02-03
ATE387911T1 (de)	2008-03-15
DE602004012279D1 (de)	2008-04-17
ES2303096T3 (es)	2008-08-01
US8367644B2 (en)	2013-02-05
WO2005009434A3 (en)	2005-06-09
DE602004012279T9 (de)	2010-01-28
SI1653943T1 (sl)	2008-08-31
DE602004012279T2 (de)	2009-07-16
DK1653943T4 (da)	2008-12-01
AU2004258867B2 (en)	2010-02-18
EP1938816B1 (en)	2010-08-25
DE602004012279T3 (de)	2010-07-15
EP1938816A2 (en)	2008-07-02
ES2303096T7 (es)	2009-06-18
AU2004258867A1 (en)	2005-02-03
CA2529507C (en)	2011-08-09
JP2012025767A (ja)	2012-02-09
WO2005009434A2 (en)	2005-02-03
DE602004028880D1 (de)	2010-10-07
DK1653943T3 (da)	2008-06-23
US7812058B2 (en)	2010-10-12
EP1653943B3 (en)	2008-07-30
CA2529507A1 (en)	2005-02-03
JP2007524633A (ja)	2007-08-30
EP1653943A2 (en)	2006-05-10
ATE478663T1 (de)	2010-09-15
ES2351581T3 (es)	2011-02-08
EP1653943B1 (en)	2008-03-05
US20110111057A1 (en)	2011-05-12
PL1653943T6 (pl)	2009-02-27
PT1653943E (pt)	2008-05-23

Publication	Publication Date	Title
PL1653943T3 (pl)	2008-09-30	Pochodne katecholu do leczenia raka
MY141661A (en)	2010-05-31	17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TNSN04065A1 (en)	2006-06-01	Treatment of acute myeloid leukemia with indolinone compounds
TWI255807B (en)	2006-06-01	Therapeutic agents
WO2001064639A3 (en)	2002-02-28	Pde iv inhibiting amides, compositions and pharmaceutical use
TW200626159A (en)	2006-08-01	Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor
TNSN03144A1 (en)	2005-12-23	Pyrrolopyrimidines as protein kinase inhibitors
MXPA04005156A (es)	2004-08-11	Antagonistas del receptor de adenosina a2a.
UA89035C2 (ru)	2009-12-25	Эфиры гидроксамовых кислот и их фармацевтическое применение
AP2003002929A0 (en)	2003-12-31	Pyrrolopyrimidines as protein kinase inhibitors
DE60014916D1 (de)	2004-11-18	Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
IL184116A0 (en)	2007-10-31	Use of thiazolidinone derivatives as antiangiogenic agents
PL342614A1 (en)	2001-06-18	Anticarcinogenic drugs
MXPA05005790A (es)	2005-10-18	Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
TW200510384A (en)	2005-03-16	Novel farnesyl protein transferase inhibitors as antitumor agents
ATE447953T1 (de)	2009-11-15	Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
WO2002074756A3 (de)	2002-12-12	Urokinase-inhibitoren
SE0201837D0 (sv)	2002-06-14	Chemical compounds
TW200730177A (en)	2007-08-16	4 anilino-3-quinolinecarbonitriles for the treatment of cancer
SE0103272D0 (sv)	2001-09-28	Chemical compounds
MXPA05013717A (es)	2006-03-08	Derivados de acido 2-etoxi-2-fenilpropionico para el tratamiento de trastornos de lipido.
AP2002002669A0 (en)	2002-12-31	Hygromycin a derivatives for the treatment of bacterial and protozoal infections.
MXPA06000651A (es)	2006-03-30	Uso de derivados de indazol para el tratamiento de dolor neuropatico.
AU4485101A (en)	2001-09-24	Antiviral therapy
KR100401973B1 (en)	2003-10-17	Pharmaceutical composition for inhibiting the activity of phosphodiesterase